A

Akebia Therapeutics

D
AKBA
USD
-0.125
(-6.2814%)
Market Closed
181,992.00
Volume
-0.22
EPS
-
Div Yield
-8.880952
P/E
392,187,511.65
Market Cap
Today
-6.2814%
1 Week
11.677%
1 Month
41.288%
6 Months
33.692%
12 Months
69.545%
Year To Date
52.869%
All Time
0%

Title:
Akebia Therapeutics

Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease,in adult patients, HIF-PH inhibitors in preclinical development.
Do you need help or have a question?